buagafuran

Buagafuran is a novel small molecule anxiolytic agent developed for the treatment of anxiety disorders. It has demonstrated significant activity in several animal models of anxiety, such as the elevated plus maze (EPM) test, rat social interaction test, and safety signal withdrawal test. The mechanism of action involves modulation of central monoamine neurotransmitters and inhibition of neuronal delayed rectifier potassium channels. Buagafuran undergoes extensive metabolism primarily via CYP3A and CYP2E enzymes. In phase I clinical trials, it was well tolerated at multiple doses up to 120 mg twice daily in healthy volunteers[6][8].

Other names

4-butyl-alpha-agarofuran4-butyl-α-agarofuran(+)-buagafuran